Simulation model to predict the fate of ciprofloxacin in the environment after wastewater treatment

Journal of Environmental Science and Health - Part A Toxic/Hazardous Substances and Environmental Engineering

Volumn 48, Issue 7, 2013, Pages 675-685

  Harris, Suvi ^a   Morris, Carol ^b   Morris, Dearbhaile ^b   Cormican, Martin ^b   Cummins, Enda ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Ciprofloxacin; hospital effluent; minimum inhibitory concentration; Monte Carlo simulation; probability; resistance.

Indexed keywords

ACCEPTABLE DAILY INTAKES; ANTIMICROBIAL PRESENCE; CIPROFLOXACIN; FORMATION POTENTIAL; HOSPITAL EFFLUENT; MINIMUM INHIBITORY CONCENTRATION; MONTE- CARLO SIMULATIONS; WASTEWATER TREATMENT PLANTS;

ANTIBIOTICS; COMPUTER SIMULATION; ELECTRIC RESISTANCE; HOSPITALS; MICROORGANISMS; MONTE CARLO METHODS; PROBABILITY; TOXICITY; WASTEWATER TREATMENT;

EFFLUENTS;

CIPROFLOXACIN; SEA WATER;

ARTICLE; EFFLUENT; EFFLUENT TOXICITY; ENVIRONMENTAL EXPOSURE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PREDICTION; SEA POLLUTION; SIMULATION; SLUDGE; SOIL POLLUTION; WASTE WATER MANAGEMENT; WASTE WATER TREATMENT PLANT;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; COMPUTER SIMULATION; HOSPITALS; MICROBIAL SENSITIVITY TESTS; MODELS, CHEMICAL; MONTE CARLO METHOD; SOIL; WASTE DISPOSAL, FLUID; WATER POLLUTANTS, CHEMICAL; WATER PURIFICATION;

EID: 84876346884     PISSN: 10934529     EISSN: 15324117     Source Type: Journal    
DOI: 10.1080/10934529.2013.744568     Document Type: Article

References (63)

1. Piddock, L.J.V. The crisis of no new antibiotics-what is the way forward Lancet Infect. Dis. 2011, 12(3), 249-253.
2. Andersson, D.I.; Hughes, D. Antibiotic resistance and its cost: is it possible to reverse resistance Nat. Rev. Microbiol. 2010, 8(4), 260-271.
3. Bergman, M.; Huikko, S.; Pihlajamaki, M.; Laippala, P.; Palva, E.; Huovinen, P.; Seppala, H. Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. Clin. Infect. Dis. 2004, 38(9), 1251-1256.
4. Bergman, M.; Nyberg, S.T.; Huovinen, P.; Paakkari, P.; Hakanen, A.J. Association between antimicrobial consumption and resistance in Escherichia coli. Antimicrob. Agents. Chemother. 2009, 53(3), 912-917.
5. Kummerer, K. Resistance in the environment. J. Antimicrob. Chemother. 2004, 54(2), 311-20.
6. Vander Stichele, R.H.; Elseviers, M.M.; Ferech, M.; Blot, S.; Goossens, H. Hospital consumption of antibiotics in 15 European countries: results of the ESAC Retrospective Data Collection (1997-2002). J. Antimicrob. Chemother. 2006, 58(1), 159-167.
7. Golet, E.M.; Alder, A.C.; Giger, W. Environmental exposure and risk assessment of fluoroquinolone antibacterial agents in wastewater and river water of the Glatt Valley Watershed, Switzerland. Environ. Sci. Technol. 2002, 36(17), 3645-3651.
8. Heberer, T. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol. Lett. 2002, 131(1-2), 5-17.
9. Xu, W.-h.; Zhang, G.; Zou, S.C.; Li, X.D.; Liu, Y.C. Determination of selected antibiotics in the Victoria Harbour and the Pearl River, SouthChina using high-performance liquid chromatographyelectrospray ionization tandem mass spectrometry. Environ. Pollut. 2007, 145(3), 672-679.
10. Alexy, R.; Kummerer, K. Antibiotics for human use. In Organic Pollutants in the Water Cycle: Properties, Occurrence, Analysis and Environmental Relevance of Polar Compounds. Eds.; Reemtsma, T.; Jekel, M.Wiley-VCHVerlagGmbH&Co. KGaA.Weinheim, FRG, 2006; 65-86.
11. Harris, S.; Cormican, M.; Cummins, E. Antimicrobial residues and antimicrobial-resistant bacteria: impact on the microbial environment and risk to human health-A review. Hum. Ecol. Risk Assess. 2012, 18(4), 767-809.
12. Blondeau, J.M. Fluoroquinolones: Mechanism of action, classification, and development of resistance. Surv. Ophthalmol. 2004, 49(2, Suppl. 2), S73-S78.
13. Parry, C.M. Fluoroquinolone Resistance: challenges for disease control. In Antimicrobial Resistance: Beyond the Breakpoint. Eds.; Weber, J.T. Karger, Basel, Switzerland, 2010; 35-50.
14. Mortensen, N.P.; Fowlkes, J.D.; Maggart, M.; Doktycz, M.J.; Nataro, J.P.; Drusano, G.; Allison, D.P. Effects of sub-minimum inhibitory concentrations of ciprofloxacin on enteroaggregative Escherichia coli and the role of the surface protein dispersin. Int. J. Antimicrob. Agents 2011, 38(1), 27-34.
15. DuPont, H.L.; Jiang, Z.D.; Ericsson, C.D.; Adachi, J.A.; Mathewson, J.J.; DuPont, M.W.; Palazzini, E.; Riopel, L.M.; Ashley, D.; Sandoval, F.M. Rifaximin versus Ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind Clinical Trial. Clin. Infect. Dis. 2001, 33(11), 1807-1815.
16. Wanke, C.A.;Gerrior, J.; Blais, V.;Mayer,H.; Acheson, D. Successful treatment of diarrheal disease associated with Enteroaggregative Escherichia coli in adults infected with human immunodeficiency virus. J. Infect. Dis. 1998, 178(5), 1369-1372.
17. Mendez Arancibia, E.; Pitart, C.; Ruiz, J.; Marco, F.; Gascon, J.; Vila, J. Evolution of antimicrobial resistance in enteroaggregative Escherichia coli and enterotoxigenic Escherichia coli causing traveller's diarrhoea. J. Antimicrob. Chemother. 2009, 64(2), 343-347.
18. Cohen, M.B.;Nataro, J.P.; Bernstein,D.I.; Hawkins, J.;Roberts,N.; Staat, M.A. Prevalence of diarrheagenic Escherichia coli in acute childhood enteritis: a prospective controlled study. J. Pediatr. 2005, 146(1), 54-61.
19. Nataro, J.P.; Mai, V.; Johnson, J.; Blackwelder, W.C.; Heimer, R.; Tirrell, S.; Edberg, S.C.; Braden, C.R.; Morris, J.G.; Hirshon, J.M. Diarrheagenic Escherichia coli infection in Baltimore, Maryland, and New Haven, Connecticut. Clin. Infect. Dis. 2006, 43(4), 402-407.
20. Bartlett, J.G.; Belitsos, P.C.; Sears, C.L. AIDS enteropathy. Clin. Infect. Dis. 1992, 15(4), 726-735.
21. Watson, A.; Samore, M.H.; Wanke, C.A. Diarrhea and quality of life in ambulatory HIV-infected patients. Dig. Dis. Sci. 1996, 41(9), 1794-1800.
22. Glandt, M.; Adachi, J.A.; Mathewson, J.J.; Jiang, Z.D.; DiCesare, D.; Ashley, D.; Ericsson, C.D.; DuPont, H.L. Enteroaggregative Escherichia coli as a cause of traveler's diarrhea: clinical response to ciprofloxacin. Clin. Infect. Dis. 1999, 29(2), 335-338.
23. Yamamoto, T.; Echeverria, P.; Yokota, T. Drug resistance and adherence to human intestines of enteroaggregative Escherichia coli. J. Infect. Dis. 1992, 165(4), 744.
24. Okhuysen, P.C.; and DuPont, H.L. Enteroaggregative Escherichia coli (EAEC): a cause of acute and persistent diarrhea of worldwide importance. J. Infect. Dis. 2010, 202(4), 503-505.
25. European Commission. Action plan against the rising threats from Antimicrobial Resistance; Author: Brussels. 2011.
26. SFT, Norwegian Pollution Control Authority. Human and veterinary pharmaceuticals, narcotics, and personal care products in the environment. InReport 2325/2007. 2007; 106,Author: OSIO.Available at http://www.klif.no/ publikasjoner/2325/ta2325.pdf
27. Harris, S.; Cormican, M.; Cummins, E. Risk ranking of antimicrobials in the environment from human consumption: an Irish case study. Hum. Ecol. Risk Assess. In press, 2012.
28. Vasconcelos, T.G.; Henriques, D.M.; K onig, A.; Martins, A.F.; Kummerer, K. Photo-degradation of the antimicrobial ciprofloxacin at high pH: identification and biodegradability assessment of the primary by-products. Chemosphere 2009, 76(4), 487-493.
29. Health Protection Surveillance Centre. Antimicrobial Consumption and Resistance. 2009, 102-109. Author: Ireland. Available at http://www.hpsc. ie/hpsc/A-Z/MicrobiologyAntimicrobial Resistance/ EuropeanAntimicrobialResistanceSurveillanceSystem EARSS/ EARSSSurveillanceReports/AnnualReports/File,12544, en.pdf
30. Health Protection Surveillance Centre. EARS-Net Report for Quarter 1 2011. 2011. Author: Ireland. Available at http://www.hpsc.ie/hpsc/A-Z/ MicrobiologyAntimicrobialResistance/ EuropeanAntimicrobialResistanceSurveillanceSystemEARSS/EARSSSurveillanceReports/ 2011Reports/File,12753,en.pdf
31. Vila, J. Fluoroquinolone resistance. Frontiers in antimicrobial resistance: A tribute to Stuart B. Levy. White, D.G.; Alekshun, M.N.; McDermott, P.F., Eds.; American Society forMicrobiology:Washington, DC, 2005; 41-52.
32. The European Committe on Antimicrobial Susceptibility Testing. Tables of QC targets and ranges v1.3. 2010, 2. Author: Sweden.
33. Palisade, @Risk 5.0. 2009. Palisade Corp.: Newfield, NY. Available at http://www.palisade.com/risk/
34. Cummins, E.; Kennedy, R.; Cormican,M. Quantitative risk assessment of Cryptosporidium in tapwater in Ireland. Sci.TotalEnviron. 2010, 408(4), 740-53.
35. Domenech X.; Ribera,M.; Peral, J. Assessment of pharmaceuticals fate in a model environment. Water Air Soil Pollut. 2011, 218(1), 413-422.
36. Hoffken,G.; Lode,H.; Prinzing,C.; Borner,K.;Koeppe, P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob. Agents Chemother. 1985, 27(3), 375.
37. Bergan, T.; Thorsteinsson, S.; Solberg, R.; Bjornskau, L.; Kolstad, I.; and Johnsen, S. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. Am. J. Med. 1987, 82(4A), 97-102.
38. Lettieri, J.T.; Rogge, M.C.; Kaiser, L.; Echols, R.M.; Heller, A.H. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 1992. 36(5), 993-996.
39. Wingender,W.; Graefe, K.H.; Gau,W.; F orster, D.; Beermann, D.; Schacht, P. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur. J. Clin.Microbiol. Infect. Dis. 1984. 3(4), 355-359.
40. Wagenlehner, F.M.E.; Kinzig-Schippers, M.; Tischmeyer, U.; Wagenlehner, C.; Sorgel, F.; Dalhoff, A.; Naber, K.G. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Int. J. Antimicrob. Agents 2006, 27(1), 7-14.
41. Davis, R.L.; Koup, J.R.; Williams-Warren, J.; Weber, A.; Heggen, L.; Stempel, D.; Smith, A.L. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob. Agents Chemother. 1987. 31(6), 915-919.
42. Wise, R.; Lockley, R.M.;Webberly, M.; Dent, J. Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob. Agents Chemother. 1984. 26(2), 208-210.
43. Dick, E.R.; Ferguson, J.A.E.; Duddy, A.M.; Kiely, D. Primary treatment options for fish processing effluent in Ireland: pilot scale trials of physicochemical and biological treatments. In EnvironmentalMonitoring and Biodiagnostics of Hazardous Contaminants. Eds.; Healy, M.;Wise,D.L.;Moo-Young,M. Kluwer Academic Publishers: Dordrecht, The Netherlands, 2001; 328.
44. Githinji L.; Musey, M.; Ankumah, R. Evaluation of the fate of ciprofloxacin and amoxicillin in domestic wastewater. Water Air Soil Pollut. 2011. 219, 1-11.
45. Karnjanapiboonwong, A.; Suski, J.; Shah, A.; Cai, Q.; Morse, A.; Anderson, T. Occurrence of PPCPs at a wastewater treatment plant and in soil and groundwater at a land application site. Water Air Soil Pollut. 2011. 216(1), 257-273.
46. Cummins, E.; Adkin, A. Exposure assessment of TSEs from the land spreading of meat and bone meal. Risk Anal. 2007, 27(5), 1179-1202.
47. Hartnett, M. A Brief Report on Mutton Island Discharge and ResidenceTimes of Galway Bay.National University of Ireland, Galway; 2009.
48. Al-Ahmad, A.; Daschner, F.D.; Kummerer, K. Biodegradability of cefotiam, ciprofloxacin,meropenem, penicillin g, and sulfamethoxazole and inhibition ofwastewater bacteria.Arch. Environ. Contam. Toxicol. 1999, 37(2), 158-163.
49. Law, A.M.; Kelton,W.D. Simulation modeling and analysis. 3rd Ed. McGraw-Hill: New York, 1981; 264-290.
50. Suter, G.W. II. Ecological Risk Assessment. CRC Press/Lewis Publishers: Boca Raton, FL, 1993.
51. Solomon, K.; Giesy, J.; Jones, P. Probabilistic risk assessment of agrochemicals in the environment. Crop Prot. 2000. 19(8-10), 649-655.
52. Tannenbaum, L.V.; Johnson, M.S.; Bazar, M. Application of the hazard quotient method in remedial decisions: a comparison of human and ecological risk assessments. Hum. Ecol. Risk Assess. 2003, 9(1), 387-401.
53. EU. White Paper. Strategy for a future chemicals policy, COM (2001) 88Final. 2001 05/11/10];Available from: http://www.isopa. org/isopa/uploads/ Documents/documents/White%20Paper.pdf.
54. Madden, J.C.; Enoch, S.J.;Hewitt, M.; Cronin, M.T.D. Pharmaceuticals in the environment: good practice in predicting acute ecotoxicological effects. Toxicol. Lett. 2009. 185(2), 85-101.
55. Kaiser, K.L.E.; Dearden, J.C.; Klein, W. Short communication: a note of caution to users of ECOSAR.Water Qual.Res. J. Can. 1999. 34(1), 179-182.
56. Sanderson, H.; Johnson,D.J.;Reitsma,T.;Brain,R.A.;Wilson,C.J.; Solomon, K.R. Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regul. Toxicol. Pharmacol. 2004, 39(2), 158-183.
57. Jeong, S.H.; Song,Y.K.; Cho, J.H. Risk assessment of ciprofloxacin, flavomycin, olaquindox and colistin sulfate based on microbiological impact on human gut biota. Regul. Toxicol. Pharmacol. 2009, 53(3), 209-216.
58. ECOSAR. Ecological Structure Activity Relationships (ECOSAR) 2008 [cited 2011 29th March]; Available from: http://www.epa. gov/oppt/newchems/tools/ 21ecosar.htm.
59. Cummins,E.The role of quantitative risk assessment in the management of foodborne biological hazards. Int. J. Risk Assess. Manage. 2008, 8(3), 318-330.
60. Livermore, D.M.; Blaser, M.; Carrs, O.; Cassell, G.; Fishman, N.; Guidos, R.; Levy, S.; Powers, J.; Norrby, R.; Tillotson, G. Discovery research: the scientific challenge of finding new antibiotics. J. Antimicrob. Chemother. 2011, 66(9), 1941-1944.
61. European Commission. Disposal and recycling routes for sewage sludge. Part 2-Regulatory report: part 2. 2001; 76-79. Author: Brussels. Available at http://ec.europa.eu/environment/waste/sludge/pdf/sludge disposal2.pdf
62. Pourcher, A.-M.; Françoise, P.B.; Virginie, F.; Agnieszka, G.; Vasilica, S.; Gerard, M. Survival of faecal indicators and enteroviruses in soil after land-spreading of municipal sewage sludge. Appl. Soil Ecol. 2007, 35(3), 473-479.
63. Lopez-Pila, J.M.; Szewzyk, R. Estimating the infection risk in recreational waters from the faecal indicator concentration and from the ratio between pathogens and indicators. Water Res. 2000, 34(17), 4195-4200.